|1.||Kramer, Benjamin: 24 articles (02/2014 - 01/2010)|
|2.||Higgins, Mark: 18 articles (09/2014 - 01/2007)|
|3.||Owen, Roger: 17 articles (05/2012 - 12/2007)|
|4.||Lawrence, David: 16 articles (08/2015 - 06/2010)|
|5.||Cazzola, Mario: 14 articles (05/2015 - 07/2005)|
|6.||Banerji, Donald: 11 articles (11/2015 - 01/2012)|
|7.||Matera, Maria Gabriella: 9 articles (07/2015 - 07/2005)|
|8.||Dahl, Ronald: 9 articles (06/2015 - 10/2007)|
|9.||Mahler, Donald A: 8 articles (11/2015 - 07/2010)|
|10.||Donohue, James F: 8 articles (10/2015 - 07/2010)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "The first trial showed a significantly higher efficacy of indacaterol vs. placebo in patients with chronic obstructive pulmonary disease (COPD). "
03/05/2012 - "In short-term trials (≤21 days) in patients with COPD, once-daily indacaterol 150 or 300 μg significantly improved lung function, exercise endurance and lung hyperinflation relative to placebo. "
12/03/2010 - "COPD exacerbations and symptoms, and health-related quality of life were also significantly improved for indacaterol versus placebo recipients in some studies. "
05/01/2015 - "The results of the pivotal Phase III IGNITE and EXPEDITION programs show that QVA149 (indacaterol/glycopyrronium FDC) is able to elicit a significant improvement in lung function and patient-reported outcomes, including breathlessness and rescue medication use, reduced rates of COPD exacerbations and health-related quality of life when compared with current standard of care. "
01/01/2015 - "Twelve weeks of indacaterol improved respiratory function and quality of life, but did not significantly affect physical activity in patients with moderate-to-severe COPD."
|2.||Dyspnea (Shortness of Breath)
05/01/2012 - "Indacaterol 150 μg provided comparable improvement in dyspnea, while indacaterol 300 μg demonstrated the greatest response overall."
05/01/2012 - "Overall, indacaterol 150 μg showed the greatest efficacy for SGRQ and indacaterol 300 μg for FEV(1) and Transition Dyspnea Index. "
11/01/2012 - "Similarly, indacaterol signifi cantly improved dyspnea (61% greater likelihood of achieving an MCID in TDI, P = .008) and health status (21% greater likelihood of achieving an MCID in St. George’s Respiratory Questionnaire, P 5 .04) than TD-LABA. "
02/01/2011 - "The therapeutic potential for indacaterol is supported by data on patient-reported outcomes with an improvement in symptoms such as dyspnea, exercise capacity and quality of life, and a reduction in exacerbations. "
01/01/2013 - "The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled trials. "
|3.||Asthma (Bronchial Asthma)
07/01/2008 - "Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma."
11/01/2010 - "This study evaluated the 24-h bronchodilator efficacy of indacaterol in Japanese patients with asthma. "
07/01/2008 - "To investigate the bronchodilator efficacy of indacaterol in patients with persistent asthma. "
09/01/2014 - "Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. "
12/01/2008 - "Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study."
|4.||Obstructive Lung Diseases (Obstructive Lung Disease)
|4.||Bronchodilator Agents (Bronchodilators)
|7.||Glycopyrrolate (Glycopyrronium Bromide)
|9.||mometasone furoate (mometasone)
|10.||maleic acid (maleate)
|1.||Nebulizers and Vaporizers (Inhaler)
|2.||Activities of Daily Living (ADL)
|3.||Dry Powder Inhalers
|5.||Respiratory Therapy (Therapy, Respiratory)